Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic burden and healthcare resource utilization
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of EGFR-mutated non-small-cell lung cancer

Economic burden and healthcare resource utilization

1 evidence topic · 1 source

U.S. healthcare resource use and costs

“409 patients with EGFRm advanced NSCLC” (opens the source at this quote in a new tab)
“Mean all-cause costs PPPM were $27 751 in 1L, $28 971 in 2L, and $31 251 in 3L.” (opens the source at this quote in a new tab)